Posted by Michael Wonder on 22 May 2025
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
22 May 2025 - Dostarlimab, when used in combination with platinum-based chemotherapy, can be used as an option for the treatment of adults with primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency when systemic therapy is suitable.
Dostarlimab can only be used if GSK provides it according to the commercial arrangement.
